Neurofibrosarcoma - Pipeline Insight, 2025
Description
DelveInsight’s, Neurofibrosarcoma - Pipeline Insight, 2025,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Neurofibrosarcoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Neurofibrosarcoma: Overview
Neurofibromatosis (NF) is a progressive and autosomal dominant inherited disorder of the nervous system which causes tumors to form on the nerves anywhere in the body, at any time. Neurofibromatosis skin lesions are typically flat, pigmented patches but occasionally are elevated flesh-colored bumps. NF1 and NF2 are inherited in an autosomal dominant pattern, with an approximately 50% rate of de novo mutations in each. The genetic mechanism of SWN is more complex and the rate of new mutations probably lies between 50% and 80%. Schwannomatosis (SWN) is the rarest form of these three conditions and is genetically and clinically distinct from NF1 and NF2. In most cases, symptoms of NF1 are relatively mild, allowing patients to live normal and productive lives. However, the disorder can also be debilitating and, in some cases, life-threatening.
""Neurofibrosarcoma - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Neurofibrosarcoma pipeline landscape is provided which includes the disease overview and Neurofibrosarcoma treatment guidelines. The assessment part of the report embraces, in depth Neurofibrosarcoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Neurofibrosarcoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
NFX-179: NFlection Therapeutics
NFX-179 is an investigational mitogen-activated protein kinase kinase (MEK) inhibitor. NFX-179 is a ""soft"" (metabolically labile) drug, which, when formulated as NFX-179 Gel for topical application, is designed to concentrate at the dermal site of action but degrade in systemic circulation, thereby significantly reducing side effects compared to systemically available MEK inhibitors.
Sirolimus: Nobelpharma
Sirolimus inhibits T lymphocyte activation and proliferation that occurs in response to antigenic and cytokine (Interleukin IL-2, IL-4, and IL-15) stimulation by a mechanism that is distinct from that of other immunosuppressants. Sirolimus also inhibits antibody production. In cells, sirolimus binds to the immunophilin, FK Binding Protein-12 (FKBP-12), to generate an immunosuppressive complex. The sirolimus: FKBP-12 complex has no effect on calcineurin activity. This complex binds to and inhibits the activation of the mammalian Target of Rapamycin (mTOR), a key regulatory kinase. This inhibition suppresses cytokine-driven T-cell proliferation, inhibiting the progression from the G1 to the S phase of the cell cycle
Further product details are provided in the report……..
Neurofibrosarcoma: Therapeutic Assessment
This segment of the report provides insights about the Neurofibrosarcoma drugs segregated based on following parameters that define the scope of the report, such as:
Neurofibrosarcoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Neurofibrosarcoma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Neurofibrosarcoma drugs.
Neurofibrosarcoma Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Neurofibrosarcoma: Overview
Neurofibromatosis (NF) is a progressive and autosomal dominant inherited disorder of the nervous system which causes tumors to form on the nerves anywhere in the body, at any time. Neurofibromatosis skin lesions are typically flat, pigmented patches but occasionally are elevated flesh-colored bumps. NF1 and NF2 are inherited in an autosomal dominant pattern, with an approximately 50% rate of de novo mutations in each. The genetic mechanism of SWN is more complex and the rate of new mutations probably lies between 50% and 80%. Schwannomatosis (SWN) is the rarest form of these three conditions and is genetically and clinically distinct from NF1 and NF2. In most cases, symptoms of NF1 are relatively mild, allowing patients to live normal and productive lives. However, the disorder can also be debilitating and, in some cases, life-threatening.
""Neurofibrosarcoma - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Neurofibrosarcoma pipeline landscape is provided which includes the disease overview and Neurofibrosarcoma treatment guidelines. The assessment part of the report embraces, in depth Neurofibrosarcoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Neurofibrosarcoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence R&D Neurofibrosarcoma. The therapies under development are focused on novel approaches to treat/improve Neurofibrosarcoma.
NFX-179: NFlection Therapeutics
NFX-179 is an investigational mitogen-activated protein kinase kinase (MEK) inhibitor. NFX-179 is a ""soft"" (metabolically labile) drug, which, when formulated as NFX-179 Gel for topical application, is designed to concentrate at the dermal site of action but degrade in systemic circulation, thereby significantly reducing side effects compared to systemically available MEK inhibitors.
Sirolimus: Nobelpharma
Sirolimus inhibits T lymphocyte activation and proliferation that occurs in response to antigenic and cytokine (Interleukin IL-2, IL-4, and IL-15) stimulation by a mechanism that is distinct from that of other immunosuppressants. Sirolimus also inhibits antibody production. In cells, sirolimus binds to the immunophilin, FK Binding Protein-12 (FKBP-12), to generate an immunosuppressive complex. The sirolimus: FKBP-12 complex has no effect on calcineurin activity. This complex binds to and inhibits the activation of the mammalian Target of Rapamycin (mTOR), a key regulatory kinase. This inhibition suppresses cytokine-driven T-cell proliferation, inhibiting the progression from the G1 to the S phase of the cell cycle
Further product details are provided in the report……..
Neurofibrosarcoma: Therapeutic Assessment
This segment of the report provides insights about the Neurofibrosarcoma drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Neurofibrosarcoma
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Molecule Type
- Small molecule
- Cell Therapy
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Neurofibrosarcoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Neurofibrosarcoma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Neurofibrosarcoma drugs.
Neurofibrosarcoma Report Insights
- Neurofibrosarcoma Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Neurofibrosarcoma drugs?
- How many Neurofibrosarcoma drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Neurofibrosarcoma?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Neurofibrosarcoma therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Neurofibrosarcoma and their status?
- What are the key designations that have been granted to the emerging drugs?
- Daiichi Sankyo
- Chia Tai Tianqing Pharmaceutical Group
- Mirati Therapeutics
- Astex Pharmaceuticals
- Ascentage Pharma Group
- Apexigen
- Nobelpharma
- Pfizer
- SpringWorks Therapeutics
- NFlection Therapeutics
- PLX3397
- AL2846
- MRTX1719
- ASTX727
- APG-115
- APX005M
- Sirolimus
- Tanezumab
- Mirdametinib
- NFX-179
Table of Contents
120 Pages
- Introduction
- Executive Summary
- Neurofibrosarcoma: Overview
- What is Neurofibrosarcoma?
- Types of Neurofibrosarcoma
- Causes
- Epidemiology and Risk Factors
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Neurofibrosarcoma– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Sirolimus: Nobelpharma
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- ASTX727: Astex Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- MRTX1719: Mirati Therapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical Stage Products
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Neurofibrosarcoma Key Companies
- Neurofibrosarcoma Key Products
- Neurofibrosarcoma- Unmet Needs
- Neurofibrosarcoma- Market Drivers and Barriers
- Neurofibrosarcoma- Future Perspectives and Conclusion
- Neurofibrosarcoma Analyst Views
- Neurofibrosarcoma Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
